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Dear Colleague: 
After the challenges of this past fall, I hope the holidays left you rested and with 
renewed energy to tackle the new year. Please accept my best wishes for 2006 and for 
the new opportunities we will have to continue our progress in eliminating tuberculosis. 
The 2005 Program Managers Course was held October 24–28, 2005, at the Sheraton 
Colony Square Hotel in Atlanta, Georgia. About 40 persons attended the course this 
year. Next year the Division of Tuberculosis Elimination (DTBE) will add a section on 
laboratory issues, which will be an important enhancement to this training course with 
excellent reviews. I would like to take this opportunity to thank the course instructors 
and organizers for their outstanding efforts in making this training course such a 
successful event. Much planning and hard work goes into the development and 
presentation of these training sessions. Those involved are deserving of our thanks and 
appreciation for taking on this important task each year. 
The Advisory Council for the Elimination of Tuberculosis (ACET) met on November 16 
and 17, 2005, in Atlanta, Georgia. After the welcome by Drs. Masae Kawamura and 
Ron Valdiserri, ACET heard updates on recent activities of DTBE and of the National 
Center for HIV, STD, and TB Prevention (NCHSTP). Dr. Valdiserri reported that  
Dr. Janet Collins, who had served as Acting Director of NCHSTP since June 2004, was 
named Director of the National Center for Chronic Disease Prevention and Health 
Promotion (NCCDPHP) in August 2005, and that a permanent NCHSTP director would 
be named in November. We have since learned that Kevin Fenton, M.D., Ph.D., has 
been selected as Director of NCHSTP. Dr. Fenton has been serving in the Division of 
STD Prevention as Chief of CDC’s Syphilis Elimination Effort since January 2005, and 
has worked in research, epidemiology, and the prevention of HIV and other STDs since 
1995. Dr. Fenton was previously the Director of the HIV and STI Department at the 
United Kingdom’s Health Protection Agency. We welcome Dr. Fenton to this new 
position and look forward to working with him in the important work of our center. 
Dr. Michael Iademarco gave the DTBE Director’s Report in my absence. He reported 
that DTBE had completed eight Epi-aids in 2005, three of which involved Hmong 
refugees in Thailand and in California. He reported that in preliminary evaluation 
findings for the U.S.-Mexico Binational Card project, political will remains strong in 
support of the project. The evaluation has led to improvements, and the project is 
expanding to new sites; but insufficient funding is a critical constraint. He reported that a 
number of DTBE guidelines were at or near completion (they have since been 
published): the latest statement on controlling tuberculosis in the United States came 
out in November 2005 in the Morbidity and Mortality Weekly Report (MMWR); 
guidelines on the use of QuantiFERON-Gold, on conducting contact investigations, and 
on preventing the transmission of M. tuberculosis in health care settings were published 
in December in the MMWR. Please see the “New CDC Publications” section of this 
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issue for the citations of these publications. Recommendations on managing TB in 
correctional settings are expected in 2006. We heard a report from Mr. Joe Posid of the 
Bioterrorism Preparedness and Response Program within the Coordinating Center for 
Infectious Diseases (of which NCHSTP is now a part) on CDC activities related to 
assessing biological agents of public health importance. With CDC working in concert 
with the Department of Homeland Security and DHHS, these activities will result in an 
updated list of potential biological terrorism agents, which should be finalized in 2006. 
Dr. Valerie Robison, DTBE’s surveillance team leader, gave an update on CDC’s TB 
surveillance systems, and Dr. Tom Navin, chief of the Surveillance, Epidemiology, and 
Outbreak Investigations Branch, provided information on new TB surveillance initiatives. 
These include the development and release of the Online TB Information System 
(OTIS), a Web-based national TB surveillance dataset that allows individual researchers 
to generate TB surveillance reports; a system for reporting adverse events caused by 
any LTBI treatment; the availability of genotyping for outbreak detection; the revision of 
the Report of Verified Case of Tuberculosis (RVCT); and the data accuracy project. 
ACET heard reviews of three articles. First, Dr. Dick Menzies of the Montreal Chest 
Institute in Canada gave a summary of the article, “Domestic returns from investment in 
the control of tuberculosis in other countries”; Drs. Kayla Laserson of DTBE and Susan 
Malone of the Division of Global Migration and Quarantine (DGMQ) were co-authors. 
The analysis showed that U.S.-funded expansion of national TB program DOTS 
programs in high-incidence countries such as Mexico would reduce TB-related illness 
and deaths among migrants, with net savings to the United States. This is based on the 
concept that U.S. financial assistance provided to the national TB programs of TB-
prevalent countries will help decrease the burden of TB in those nations; this will reduce 
the number of TB-infected persons from that country migrating to the United States, and 
this will ultimately reduce TB and TB control costs in the United States. Next Dr. Henry 
Blumberg, Hospital Epidemiologist of Grady Hospital in Atlanta, discussed “How many 
sputum specimens are necessary to diagnose pulmonary tuberculosis?” Dr. Blumberg 
presented data showing that in the high-risk, inner-city patient population at Grady, the 
number of specimens needed to diagnose pulmonary TB disease may be reduced from 
three to two; a third smear did not appear to add much information in a robust TB-
oriented health-care setting with excellent quality infection control systems in place. This 
was followed by a related discussion by Dr. Sundari Mase, a physician from California, 
on the yield of two vs. three AFB sputum smears for evaluating pulmonary TB suspects. 
Her review suggested that the mean incremental yield of a third smear is 3%–5%; if the 
yield of the first and second smears is improved, the yield of the third would be even 
lower. She pointed out that requiring only two smears would involve less work for the 
laboratory, fewer costs, and more time to perform the two smears. The “cons” would be 
decreased case detection and increased transmission, resulting in TB infection. 
Proposed next steps were to study the policy implications of two vs. three sputum 
smears and to review the WHO case definition of smear-positive pulmonary TB. 
Dr. Bill Burman of Denver Public Health and a member of the TB Trials Consortium 
presented an exciting talk on opportunities and challenges in TB clinical trials for the 
next decade. He suggested that promising new anti-TB agents may permit reduction in 
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the length of TB treatment from 6 months to 2 if clinical trials could be adequately 
funded. After an exchange of comments and questions, ACET members decided to 
draft a letter to the Secretary of DHHS advocating for additional funding for multiple TB 
control components, including clinical trials. We then heard from Ms. Kimberly Lane, 
senior advisor to the Chief Management Official of CCID, who reviewed CDC’s 
reorganization and discussed the proposed new design of CCID. 
Dr. Charles Wells gave an overview of USAID’s Tuberculosis Country Assistance 
Program (TB CAP), which is a follow-up project to the TB Coalition for Technical 
Assistance. TBCAP is a 5-year project based on a partnership between USAID and 
several international organizations, including the KNCV, ALA, ATS, WHO, CDC, and 
IUATLD. Its main components consist of advocacy and social mobilization, DOTS 
expansion, laboratory capacity building, TB/HIV services, and training and human 
resource development; its strengths are that it is an effective mechanism for 
coordination among TB organizations, it reduces duplication of efforts, and it allows 
close management of activities and high accountability for partners. Dr. Iademarco then 
discussed a USAID-funded and -sponsored project that has the goal of developing a set 
of international standards for TB care. The focus or intent is to ensure high-quality 
treatment for all patients in all settings. These standards will call for a level of care 
above the current WHO standards. A number of follow-up items were addressed, after 
which the meeting was adjourned. The group will reconvene in February 2006. 
From October 17 to 23, 2005, DTBE staff attended and participated in the 36th World 
Conference on Lung Health, the annual meeting of the International Union Against 
Tuberculosis and Lung Disease (IUATLD), in Paris, France. The theme was “Scaling up 
and sustaining effective tuberculosis, HIV, and asthma prevention and control.” CDC 
was well represented in the planning and organization of the meeting and in the 
outstanding presentations that were given. This meeting provided DTBE staff with the 
opportunity to contribute to global TB prevention and control efforts through ongoing 
collaboration with the Union, Stop TB, and other national TB prevention programs. As 
discussed during the last ACET meeting, recent publications have highlighted the 
importance of global TB control to the fulfillment of our domestic goals (Schwartzman K, 
Oxlade O, Graham Barr R, et al. Domestic returns from investment in the control of 
tuberculosis in other countries. N Engl J Med 2005; 353: 1008-1020; and Bloom BR, 
Salomon JA. Enlightened self-interest and the control of tuberculosis. N Engl J Med 
2005; 353: 1057-1059). 
Please note that the 2006 National TB Controllers Workshop will be held June 13 to 15, 
2006, in Atlanta at the Sheraton Buckhead Hotel. Details will be forwarded as they 
become available. Hope to see you there! 
Kenneth G. Castro, MD 
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HIGHLIGHTS FROM STATE AND 
LOCAL PROGRAMS 
Hurricane Katrina’s Impact on TB 
Control in the Gulf States 
On August 29, 2005, Hurricane Katrina slammed 
into the Northern Gulf of Mexico, causing 
devastation and destruction that severely 
crippled social and medical institutions in 
Louisiana, Mississippi, and Alabama. At the 
urgent request of Louisiana Governor Kathleen 
Babineaux Blanco, Texas Governor Rick Perry 
agreed to allow hurricane victims taking shelter in 
the New Orleans Superdome to be moved to the 
Houston Astrodome, which is located in Harris 
County, Texas. Texas officials agreed to allow 
the Astrodome to be used as a shelter for the 
evacuees. The Astrodome was soon filled to 
capacity with 23,000 displaced hurricane 
evacuees. An additional 120,000 displaced 
evacuees were housed in 97 shelters in other 
cities in Texas including Houston, Dallas, San 
Antonio, and dozens of smaller cities across the 
state as far north as Midland and as far west as 
El Paso. Another 100,000 persons were housed 
in hotels and motels around the state. It is 
estimated that a total of 250,000 displaced 
residents from Louisiana are now in Texas. 
On August 31, 2005, Mr. Charles DeGraw, 
Louisiana State TB Controller, called the Texas 
Department of State Health Services TB Program 
to inform the program that approximately 100 TB 
patients could be among the displaced residents. 
Mr. DeGraw noted that the Louisiana TB 
Program had been significantly impacted by the 
flood waters coming from Hurricane Katrina. 
Working with Mr. DeGraw, the Texas TB 
Program immediately began putting in place 
support systems for those areas in the state 
receiving displaced residents from Louisiana. 
Local and regional health departments in Texas 
were notified to be on the lookout for persons 
with TB. Local and regional health departments 
were told to "Think TB" at all times because 
many of the persons diagnosed in Louisiana 
might not communicate their condition to the 
medical teams working in the shelters. Shelter 
workers were told to be alert to the signs and 
symptoms of TB. If shelter residents were 
identified as having TB, those persons were to be 
taken to the shelter medical triage stations for 
evaluation and isolation, if indicated. Mr. DeGraw 
also indicated that his medication supply was 
under water and thus his program would need TB 
medications. Mr. DeGraw asked the State of 
Texas to "loan" the Louisiana TB Program the 
necessary TB drugs to continue providing 
treatment to persons staying in Louisiana. The 
state agreed to provide the necessary 
medications for Louisiana. The Texas TB 
Program also worked with VersaPharm to 
arrange for medications to be sent to Louisiana. 
Mr. Joe Ware, President of VersaPharm, 
responded by shipping all the needed 
medications to the Louisiana TB Program at no 
cost to the State of Louisiana. The Texas 
Department of State Health Service TB Program 
organized a team comprised of staff from public 
health regions, local health departments, the data 
analysis unit at the Texas Department of State 
Health Services, and the Louisiana State Health 
Department TB Program to address the issues 
surrounding the management of persons in 
shelters who are found to have TB. Mr. DeGraw 
also requested laboratory support from the Texas 
Department of State Health Services. The Texas 
TB program arranged for the Texas State 
Laboratory to provide laboratory assistance. 




The Texas State Laboratory agreed to receive 
and process TB specimens submitted by the 
State of Louisiana for evaluation. The Texas 
Laboratory provided the Louisiana TB Program 
with the containers needed to ship specimens to 
the Texas State Laboratory. As of October 31, 
there had been 307 specimens submitted to the 
Texas State Laboratory for processing. 
 
In an effort to determine if any of the displaced 
Louisiana residents living in the shelters had 
been diagnosed, the Texas TB Program worked 
with the Texas Emergency Command Center, the 
Incident Command Center in Houston, the City of 
Houston and Harris County government officials, 
the Texas State Health Service Regions, local 
health departments throughout the state of 
Texas, local hospitals, the American Red Cross, 
and countless shelters across the state to match 
known tuberculosis patients with the listing of 
shelter residents. TB program staff confidentially 
worked with shelter administrators to match the 
lists. Persons identified were then evaluated and 
placed on medication and in some cases 
hospitalized for treatment. The Texas 
Tuberculosis Program worked with the Texas 
State Pharmacy to ensure tuberculosis 
medications were stocked on the mobile 
pharmacies deployed to shelters. 
 
On September 7, 2005, Ms. Phyllis Cruise, 
Senior CDC Public Health Advisor assigned to 
Texas, was deployed to work at the Incident 
Command Center at the Houston Astrodome. 
Ms. Cruise assisted in the medical follow-up of 
persons residing in the shelters. She worked 
primarily in the three large shelters located in 
Reliant Park, which is located in Houston–Harris 
County, Texas. Reliant Park includes the Reliant 
Dome (i.e., the Astrodome), the Reliant Arena, 
and the Reliant Center. All together this complex 
housed 25,000 displaced persons. Houston also 
had another large shelter in the downtown area 
of the city, the George R. Brown Center, which 
housed 2,800 persons. Ms. Cruise assisted the 
city and county TB programs in their efforts to 
develop and deliver to shelter staff and residents 
educational messages and materials on TB, 
including the development of posters detailing 
the signs and symptoms of TB. Ms. Cruise also 
assisted city and county staff in planning 
activities for locating the persons who were on 
the patient list from Louisiana. This included 
using contacts from other agencies, both public 
and private and traditional as well as 
nontraditional sources such as the Federal 
Emergency Management Agency (FEMA). Ms. 
Cruise worked with FEMA to secure current 
addresses and telephone numbers for registered 
evacuees who had been diagnosed with TB and 
started on treatment in Louisiana. By mid- 
October, TB control officials were very happy to 
report that all TB patients who had been 
evacuated from the affected areas as a result of 
the hurricane had been accounted for. 
 
—Reported by Charles Wallace, Ph.D., M.P.H., and 
Phyllis Cruise, CDC Public Health Advisor 
Texas Department of State Health Services 
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DTBE Responds to Hurricane Katrina 
 
Following Hurricane Katrina’s landfall on August 
29, 2005, staff of DTBE worked with the National 
TB Controllers Association (NTCA) to provide 
technical and logistical support and to facilitate 
communication for the TB programs affected by 
the sudden displacement of thousands of Gulf 
Coast residents. 
 
At the request of the CDC Director’s Emergency 
Operations Center, DTBE developed resource 
materials to provide TB-related guidance to staff 
of approximately 750 shelters and evacuation 
centers in at least 18 states. Resources included 
an up-to-date list of TB program contacts, 
guidance for identifying persons in evacuation 
centers who may have TB, and a list of relevant 
TB educational resources. These were posted on 
the CDC hurricane website, as well as the DTBE 
website: http://www.cdc.gov/nchstp/tb/katrina/. 
These resources emphasized the importance of 
immediately consulting the local or state TB 
program if evacuees were or had been taking 
anti-TB medications or had symptoms suggestive 
of TB disease. Katrina-related heightened public 
health surveillance resulted in the reporting of at 
least 10 evacuees as potentially having TB. 
Although most were subsequently diagnosed 
with other conditions (e.g., lung cancer and 
infection with nontuberculous mycobacteria), two 
new cases of confirmed TB were found and 
reported. 
 
Along with many others throughout CDC and the 
U.S. Public Health Service, 18 DTBE staff were 
deployed to various locations to provide on-site 
support to areas affected by Katrina. For 
example, Ted Misselbeck and Dawn Tuckey 
were deployed to Louisiana. Other staff already 
assigned to the field, like Phyllis Cruise with the 
Texas TB Program, found that Katrina-related 
work soon demanded their full attention (see 
related article, “Hurricane Katrina’s Impact on TB 
Control in the Gulf States”). Back in Atlanta, at 
least 10 others shifted their work priorities to 
focus on support for Katrina-related activities. 
On September 2, DTBE established a Katrina 
Help Desk, with a team led by Gail Burns-Grant, 
to provide a 24/7 on-call system to respond to TB 
inquiries and to coordinate efforts by NTCA and 
the TB programs in Alabama, Louisiana, and 
Mississippi to account for all persons known by 
local public health authorities to be undergoing 
treatment for TB disease when the hurricane 
struck. Although most of the 180 TB patients in 
the most directly affected regions remained in 
their home states, others relocated to Arkansas, 
California, Colorado, Florida, Georgia, Illinois, 
Maryland, Massachusetts, Missouri, Ohio, South 
Carolina, Tennessee, Texas, and Washington 
State. Accounting for all these persons involved a 
great deal of collaboration and assistance from 
many state and local TB partners, as well as new 
partnerships with relief agencies and private 
companies to cross-match names for the 
purposes of locating displaced patients. As of 
October 13, all 180 had been located and were 
receiving follow-up attention and treatment 
continuity.  
 
—Submitted by DTBE Atlanta and field staff: 
Gaby Benenson, Gail Burns-Grant, 
Phyllis Cruise (TX), Maryam Haddad, 
Michael Iademarco, Ted Misselbeck (TN), 




During Hurricane Katrina and its aftermath, a 
new secure, online service became available to 
help hurricane-affected individuals work with their 
health professionals to gain access to their own 
electronic prescription medication records. The 
new site allows authorized physicians and 
pharmacies to get records of medications 
evacuees were using before the storm hit, 
including the specific dosages. Having this 
information will help evacuees refill their 
medication prescriptions; it will also help health 
care professionals coordinate care and avoid 
harmful errors when prescribing new 
medications. Evacuees are spread out across the 
country; therefore, this information can be 
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accessed from anywhere in the United States 
through www.KatrinaHealth.org. The urgent effort 
to make www.KatrinaHealth.org available to 
health care professionals was facilitated by the 
Office of the National Coordinator for Health 
Information Technology (ONC), within the U.S. 
Department of Health and Human Services. 
 
This project has been supported by more than 
150 organizations that have participated in the 
planning, testing, and launching of the site. 
Important data and resources were contributed 
by the American Medical Association (AMA), 
Gold Standard, the Markle Foundation, RxHub, 
SureScripts, and the Louisiana and Mississippi 
departments of health. More information 
including a press release and frequently asked 
questions (FAQs) can be found at 
www.KatrinaHealth.org. 
 
—Reported by Mark D. Fussell 
CDC Senior Management Official - Texas 
Austin, Texas 
 
Eliminating Tuberculosis Case by 
Case: An Educational Initiative by 
New England TB Programs 
 
Purpose and Goal of the TB Case Series. In an 
effort to reach several key partners using an 
educational venue, the six New England 
tuberculosis (TB) control programs organized a 
Web-based interactive “TB Case Series.” The TB 
Case Series is designed to allow providers to 
present cases that illustrate public health 
principles and practices. The goal of the TB Case 
Series is to offer a forum for 
• Discussing the public health importance 
of infectious TB 
• Describing the clinical management of 
TB, and increasing awareness of 
national recommendations for TB 
diagnosis and treatment, and 
• Discussing options for ongoing patient 
care. 
 
The course will promote standard diagnostic 
procedures and national guidelines through 
analysis and discussion of TB cases. 
Additionally, the course offers continuing 
education credit for physicians, nurses, health 
educators, and other participants. 
First Two Presentations a Big Success. On 
October 26, 2005, more than 80 persons 
participated in the first case presentation.  The 
inaugural presentation featured C. Robert 
Horsburgh, MD, a local and national expert in TB 
and HIV treatment. Dr. Horsburgh, formerly with 
CDC, is now the Chair of the Department of 
Epidemiology and the Director of the Prevention 
Research Center at the Boston University School 
of Public Health and the Boston University 
Medical Center. Dr. Horsburgh laid the 
groundwork for future case presentations and 
skillfully led the discussion, drawing participants 
into an active dialogue around the case. The 
second presentation was given in October by C. 
Fordham von Reyn, MD, Chair, Infectious 
Diseases and International Health at Dartmouth-
Hitchcock Medical Center. The presentation 
skillfully combined a case and review of TB-
related lymphadenopathy. About 45 participants 
from New England called in to listen and discuss 
the case and other cases. 
 
Evidence of the Need for Educational Activities 
Targeting TB Providers. Several sources of 
evidence indicate that TB care providers have 
ongoing educational needs. These sources 
include 1) a regional education needs 
assessment, 2) studies documenting 
nonadherence to national standards and 
guidelines by private providers, and 3) a CDC 
study documenting that 40% of private providers 
do not use a recommended treatment regimen 
(Sumartojo EM, Geiter LJ, Miller B, Hale BE. Can 
physicians treat tuberculosis? Report on a 
national survey of physician practices. Am J 
Public Health 1997;87:2008-11). In addition, in 
2004 DTBE and the three Model TB Centers 
developed a national strategic plan for TB 
training and education in conjunction with experts 
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in TB and education, health care providers, and 
other partners. The plan states that private 
providers who serve high-risk populations need 




Thanks to the Organizers. A coordinating group 
representing the New England TB programs, the 
Regional Training and Medical Consultation 
Centers (RTMCCs), and DTBE organized the 
course. These contributors to the New England 
TB Case Series included Kathy Hursen 
(Massachusetts TB Program), Judy Proctor (New 
Hampshire TB Program), Rajita Bhavaraju 
(Northeast RTMCC), and Mark Lobato, Subroto 
Banerji, Regina Bess, and Judy Gibson (DTBE). 
 
—Reported by Erin Howe, Regional TB Medical 
Consultation Consortium – New England 
Kathy Hursen, RN, MS, Massachusetts 
Div of TB Prevention and Control 
Mark Lobato, MD, Div of TB Elimination, 
New England TB Consultant 
Lisa Roy, TB Educator, New Hampshire TB Program 
Div of Public Health Services 
 
Standardized Nursing Case 
Management Interventions 
Described in the Evaluation of a TB 
Targeted Testing/Treatment Project 
 
The evaluation of the CDC-funded Targeted 
Testing and Treatment of Latent TB Infection (TT 
TLTBI) Program in Arlington County, Virginia, 
provided an opportunity to capture best practices 
and develop lessons learned that could benefit 
state and local TB programs. In describing the 
program for the purpose of evaluation, the role of 
the Pediatric TB Public Health Nurse (PHN) case 
manager was described. This description was 
used to develop a nursing practice logic model. 
 
Public health nursing activities traditionally play a 
prominent role in TB control efforts. However, the 
process and the standards for those activities 
must be described before they can be evaluated. 
The TB Patient-Level Care Model 2002, 
developed by the National TB Nurse Consultant 
Coalition, links TB-specific recommendations 
(statement and guidelines) associated with 
theory-based multiple determinants of behavior 
(from the patient’s perspective) with the NANDA 
taxonomy of nursing practice, the Nursing 
Intervention Classification, and the Nursing 
Outcome Classification. The model serves to 
describe case management, what it is expected 
to achieve, and what activities it includes.   
 
In a collaborative effort to describe the TT TLTBI 
project in Virginia for evaluation, TB PHNs at the 
local, state, and national levels applied the TB 
Patient-Level Care Model to the case manager’s 
role description and developed a nursing practice 
logic model. From this model, the team described 
process and outcome indicators for evaluation. 
Next steps include developing the tools to gather 
credible evidence, justifying conclusions based 
on this evidence, and using the lessons learned. 
 
During the NTNCC meeting held June 27, 2005, 
in Atlanta, Georgia, a partial description of the 
evaluation for the CDC-funded TT TLTBI 
program in Arlington County, Virginia, was 
presented. Virginia Thackery, Pediatric TB PHN 
case manager, presented an overview of the 
Arlington TT TLTBI Project and her role as the 
Pediatric TB PHN case manager. Judy Gibson, 
Nursing Consultant, Field Services and 
Evaluation Branch, DTBE, presented the 
methods used in developing the nursing practice 
logic model and an overview of the team-
developed model. Jane Moore, Nursing 
Consultant, Virginia Department of Health, 
presented the TB Service Plan, developed in 
Virginia, that lists nursing actions tailored to 
patient needs. The TB Service Plan was also 
used in reviewing the role description of the 
Pediatric TB PHN case manager. 
 
—Reported by Jane Moore, RN 
Virginia Department of Health, 
and Judy Gibson, RN 
Div of TB Elimination 
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TB EDUCATION AND TRAINING 
NETWORK UPDATES 
 
TB ETN Member Highlight 
 
David L. Oeser is a Health Program 
Representative for TB Control and Missouri’s 
Refugee Health Coordinator for the Missouri 
Department of Health and Senior Services. 
 
His job responsibilities include serving as a TB 
Training Focal Point, Refugee Health 
Coordinator, and Diagnostic Services Program 
Manager. He is also responsible for reviewing all 
latent TB infection reports for appropriate 
diagnosis and treatment, and providing technical 
assistance to the state’s Department of 
Corrections and all local public health agencies in 
regard to TB and refugee health. 
 
David first learned of TB ETN when he was 
browsing DTBE’s Internet home page,  
saw the link for TB ETN, and investigated it. He 
joined to keep up to date on available TB 
resources, training, and information. He is also a 
member of TB ETN’s Communications and 
Membership Subcommittee. “This is a very 
valuable resource, and I have gotten a lot of 
information from TB ETN and wanted to give 
back by contributing in some way,” David said. 
He hopes to continue the excellent work 
accomplished by the members of the 
Communications and Membership 
Subcommittee. 
 
He recently completed six TB in-services for all 
TB staff in the local public health agencies in 
Missouri. He held a TB Grand Rounds session 
via Missouri’s Telemedicine Network, during 
which several difficult TB cases were discussed 
among nurses, doctors, and other interested 
personnel. 
 
Annually, David coordinates Missouri’s TB 
Fortnight activities. Missouri’s TB Fortnight is 
held during the last 2 weeks of March to raise 
awareness about TB. David and his coworkers in 
Missouri conduct seminars, TB Grand Rounds, 
and radio interviews, and also host a Governor’s 
Proclamation event. “Missouri has had speakers 
such as Drs. Michael Iseman and Ram Koppaka 
at these functions,” he relates. 
 
In his spare time, he enjoys hiking, reading, 
researching family history, and doing cross stitch 
and plastic canvas craft work. Interestingly, David 
came to TB control after a career in the Navy. He 
retired from the U.S. Navy in 1995 after 25 years 
of service. 
 
If you’d like to join David as a TB ETN member 
and take advantage of all TB ETN has to offer, 
please send an e-mail requesting a TB ETN 
registration form to tbetn@cdc.gov. You can also 
send a request by fax at (404) 639-8960 or by 
mail at TB ETN, CEBSB, DTBE, CDC, 1600 
Clifton Rd., N.E., MS E10, Atlanta, Georgia 
30333. If you would like additional information 
about the TB ETN, visit the website at 
http://www.cdc.gov.nchstp/tb/TBETN/default.htm. 
 
—Reported by Regina Bess 
Div of TB Elimination 
 
Communications and Membership 
Subcommittee 
 
One of the goals of the TB ETN Communications 
and Membership Subcommittee during 2005 was 
to develop new methods for sharing information 
among members. To that end, the Subcommittee 
decided to use a Web board hosted by CDC on a 
trial basis. The Web board is an electronic site for 
posting messages that members can read when 
they log in. 
 
On the Web board, a discussion board was 
created for TB ETN. This discussion board has 
been open to members of the Communications 
and Membership Subcommittee on a trial basis 
starting in February 2005 and to the Cultural 
Competency subcommittee in May 2005. As part 
of this trial, three discussion board orientations 
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were conducted to familiarize subcommittee 
members with this communication tool. 
 
Initial feedback from members of these two 
subcommittees has indicated that they have 
found the discussion board difficult to use. 
Members have also indicated that they prefer to 
visit the TB ETN website to view subcommittee 
minutes and to use e-mails for correspondence. 
 
The trial use of the discussion board will continue 
for several more months. At the end of the trial, a 
determination will be made about further use of 
the discussion board. If a decision is made to 
continue using the discussion board, access to it 
may be expanded to other subcommittees. If not, 
the Communications and Membership 
Subcommittee will explore other ways to improve 
and expand information dissemination among 
members. 
 
—Reported by Linette McElroy, R.N. 
Vancouver Island Health Authority TB Clinic 
Victoria, British Columbia 
and Scott McCoy, M.Ed. 
Div of TB Elimination 
 
Cultural Competency Subcommittee 
 
The Cultural Competency Subcommittee 
welcomes Ms. Margaret Rohter, MPH, from the 
Suburban Cook County TB Sanitarium District to 
the helm as committee chair, and Mr. Bill Bower 
from the Charles Felton TB Center in New York 
as co-chair. In addition to this transition in 
leadership, the subcommittee is considering 
changing the day and time of monthly conference 
calls in an effort to enable more members to 
actively participate.  
 
During the 2005 Annual TB ETN Meeting in 
Atlanta, the subcommittee conducted a needs 
assessment among the meeting attendees. We 
would like to thank the 47 individuals who took 
the time to respond. The results were analyzed 
by Beth Kingdon and presented in a written 
report. The subcommittee will use the findings 
from this report as part of their continuing effort to 
meet the cultural competency needs of the TB 
ETN membership. 
 
Finally, if you or your colleagues have had a 
culturally challenging experience that provided 
professional growth or insight and that you would 
like to share, the subcommittee encourages you 
to contact Lauren Moschetta at the New Jersey 
Medical School National TB Center (NJMS 
NTBC), by telephone at (973) 972-1261 or by e-
mail at moschelb@umdnj.edu. Your experience 
could be presented as a case study in the NJMS 
NTBC’s Cultural Competency Newsletter. 
 
—Submitted by Joan Mangan, PhD, MST 
University of Alabama at Birmingham 
Lung Health Center 
 Div of Pulmonary, Allergy, and 
Critical Care Medicine 
 
Cultural Competency Tip 
Accessing, using, and understanding the U.S. 
health care system is difficult for almost 
everyone. However, for immigrants new to this 
country, it can sometimes seem impossible. For 
some suggestions you can use to make health 
care in the United States more accessible, 
usable, and understandable for people new to 
this country, read “In Other Words…. 
Communicating about Health with New 
Immigrants,” an article by Helen Osborne, MEd, 
OTR/L, President, Health Literacy Consulting, at 
http://www.healthliteracy.com/oncallnov2003.html 
 
TB EPIDEMIOLOGIC STUDIES 
CONSORTIUM UPDATE 
 
TBESC Task Order #3: Zero 
Tolerance for Pediatric Tuberculosis 
 
Background and Methods. Tuberculosis (TB) in 
young children represents a sentinel event and 
may indicate an undetected case of infectious TB 
in the community. The incidence of TB in young 
children is also an important indicator that 
defines insufficiencies in TB program 
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interventions to prevent TB transmission. We 
conducted this study to learn more about the 
problems encountered by TB programs in 
identifying, evaluating, and treating children <5 
years of age with TB and latent TB infection 
(LTBI). We also sought to define missed 
opportunities to prevent TB and LTBI in children 
and improve outcomes related to their evaluation 
and treatment. The study took place in three 
areas of the country with diverse populations: 
Harlem and Washington Heights in New York 
City, Alameda and San Diego counties in 
California, and Tarrant County, Texas. 
 
Results. In this study, 428 children were enrolled 
(67% in California). Of these children, 124 were 
diagnosed with TB and 304 had LTBI. The 
children had the following characteristics: 65% 
were Hispanic, 51% were born in the United 
States, and 19% were born in Mexico. Treatment 
was by directly observed therapy for 87% of TB 
cases, but for only 7% of LTBI cases. Children 
with active TB were primarily identified when they 
sought medical care for symptoms (45%) or were 
detected through contact investigations (20%). 
Children with LTBI were most often found 
through screening (44%). Three children had a 
prolonged symptomatic period before diagnosis 
(112–144 days). About 10% of children had a 
≥14 day delay from TST to chest radiograph. The 
mean time from the chest radiograph to the start 
of treatment was 5 days for children with TB and 
19 days for children with LTBI. In addition, 10% 
of children with TB and 18% of children with LTBI 
had a ≥14 day delay from radiograph to the start 
of therapy. Adherence to appointments was 
measured. Missing three or more appointments 
was experienced by 8% of children with TB and 
14% of children with LTBI. Completion of therapy 
was greater for children with TB compared with 
those who had LTBI, 82% (11% on treatment at 
the end of the study) and 58%, respectively. 
 
Conclusion. We detected important missed 
opportunities and delays in the diagnosis and 
evaluation of children with TB and LTBI. An in-
depth review of each case of pediatric TB and of 
child contacts allows health departments to 
evaluate their success in preventing TB and LTBI 
in young children. As case rates among children 
continue to decline, the possibility of eliminating 
TB in children becomes real. 
 
—Reported by Mark Lobato, MD 
Div of TB Elimination 
for the Pediatric TB Working Group, TO #3, TBESC 
 
TB TRIALS CONSORTIUM 
UPDATE 
TBTC Study Enrollment 
Study 24 is a single-arm study of largely 
intermittent, short-course therapy for patients 
with INH-resistant TB or INH intolerance. 
Enrollment closed December 2004 with a total of 
98 patients. By mid 2007, all patients will have 
reached the end of follow-up for study outcomes 
(e.g., treatment failure and relapse). 
Study 26 is a trial of short-course treatment of 
latent TB infection among contacts of active 
cases, using a 3-month, once-weekly regimen of 
isoniazid 900 mg and rifapentine 900 mg, 
compared to standard 9-month daily therapy with 
isoniazid 300 mg. As of January 19, 2006, Study 
26 enrollment was up to 5,485, over 68% of the 
intended subjects for total enrollment.  These 
5,485 subjects include 294 persons under 18 
years of age. 
Study 27 is a double-blind, placebo-controlled 
evaluation of 2-month culture conversion rates 
when substituting moxifloxacin for ethambutol in 
the 2-month intensive phase of treatment of 
pulmonary TB. A total of 336 patients were 
enrolled between July 2003 and March 2005. 
Over 50% of patients were enrolled from two 
African study sites. The first preliminary results 
were presented in May 2005. There was no 
difference between the moxifloxacin and the 
ethambutol study arms in 2-month culture 
conversion; these rates were both 71%. There 
were differences, however, between North 
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American sites and African sites, with 
significantly more North American patients 
converting their sputum to negative by 2 months 
(85%) compared to African patients (63%). 
Further analyses are ongoing. 
Study 28 is a double-blind, placebo-controlled 
study of 2-month culture conversion rates when 
substituting moxifloxacin for isoniazid in the 2-
month intensive phase of treatment of pulmonary 
TB. This isoniazid-sparing regimen for TB 
treatment is based on data from the murine 
model of tuberculosis. In the murine model, the 
substitution of moxifloxacin for isoniazid resulted 
in significant reduction in the time to sterilization 
when compared to the standard combination of 
rifampin, isoniazid, and pyrazinamide. Improved 
sputum culture conversion after 2 months of 
treatment with a moxifloxacin-containing regimen 
would support movement to phase-3 clinical trials 
of moxifloxacin-based treatment regimens of less 
than the current 6-month standard duration. 
Study 28 will enroll 410 patients from both 
domestic and international TBTC sites. 
Enrollment is expected to begin in early 2006. 
—Reported by Susan Ray, MD 
Emory University School of Medicine 
Member, Advocacy & External Relations Committee 
TB Trials Consortium 
 
CLINICAL AND HEALTH 
SYSTEMS RESEARCH BRANCH 
UPDATE 
 
Potential TB Treatment Cost Savings 
Using Moxifloxacin-Based Regimens 
 
Moxifloxacin has been proposed as a first-line 
anti-TB medication that may permit shortening of 
therapy for TB disease from 6 months to 4. In TB 
Trials Consortium Study 28, a phase-2 trial, 
moxifloxacin (M) will be substituted for isoniazid 
(H) in the initial 2-month intensive phase of TB 
treatment. The study will assess whether this 
new regimen will shorten the time to sputum 
culture conversion; studies in mice have 
suggested that it will. An anticipated 4-month 
regimen would consist of 2 months of 
moxifloxacin, rifampin, pyrazinamide, and 
ethambutol (2MRZE) followed by 2 months of 
moxifloxacin and rifampin (2MR) administered 5 
days per week. Other regimens containing 
moxifloxacin that might be considered for study in 
the future include twice-weekly dosing in both 
initial and continuation phases (2MRZE2/2MR2), 
twice-weekly dosing in both initial and 
continuation phases substituting rifapentine for 
rifampin (2MPZE2/2MP2), and a Denver-like 
regimen of 2 weeks’ daily dosing of MRZE 
followed by 6 weeks of MRZE taken twice weekly 
followed by 2 months of MR twice weekly 
(.5MRZE/1.5MRZE2/2MR2). 
  
As a follow-up to an article published in TB Notes 
No. 4, 2003, describing the potential cost savings 
of all recommended TB treatment regimens 
compared with the daily standard, we now add 
the TBTC Study 28 initial phase moxifloxacin 
study regimen with a 2MR continuation phase 
regimen. The table presents estimated costs per 
patient to TB programs and to society for 
implementing the various regimens. Direct costs 
are those incurred by TB programs for 
medications and personnel to conduct directly 
observed therapy (DOT). Total costs add patient 
productivity losses to the direct costs, to estimate 
the costs to society. All doses are assumed to be 
administered by DOT. The costs of DOT were 
estimated by applying the 2001 Medicare 
allowable charge for a home DOT visit ($49),1 
updating it to 2004 dollars ($56), and converting 
it to a cost by multiplying it by 0.502, which is the 
average cost-to-charge ratio for pulmonary 
diseases.2 Patient productivity losses are 
estimated based on computations of a daily wage 
from the Bureau of Labor Statistics Average 
Weekly Earnings,3 adjusted upwards by 22% to 
include benefits.4 Since most TB programs 
purchase their medications through the Public 
Health Service (PHS), estimates of PHS prices 
are used. All costs have been updated and are 
reported in 2004 dollars. 
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The standard regimen of 2 months of daily HRZE 
followed by 4 months of daily HR is estimated to 
cost $3,970 in direct costs and $8,162 total. The 
least costly approved regimen (at $1,469 in direct 
costs and $2,758 total) is 2 weeks of HRZE 
followed by 6 weeks of twice weekly HRZE 
followed by 4 months of isoniazid and rifapentine 
taken once weekly (0.5HRZE / 1.5HRZE2 / 
4HRPT1), which is currently restricted to use in 
HIV-uninfected patients who do not have cavitary 
disease and are not culture-positive at 2 months. 
The 2MRZE/2MR regimen, the initial phase of 
which is to be investigated in Study 28, is 
estimated to cost $2,843 in direct costs and 
$5,423 total, a potential savings of 34% over the 
standard daily regimen. While it is not the least 
costly regimen, the proposed Study 28–derived 
4-month regimen, if of equal efficacy compared 
to approved regimens, would add to our list of 
potential treatment choices that might be quite 
cost-effective (and very likely to be cost-saving) 
over the standard daily 6-month regimen. This 
would be especially true if a new 4-month 
regimen resulted in significantly greater 
adherence to treatment and completion, caused 
similar or fewer adverse events, and was not 
associated with initial or acquired drug resistance 
in the populations in which it will be used. The 
other potential moxifloxacin regimens are 
projected to be among the least expensive 
regimens ever, with 2MRZE2/2MR2 potentially 
saving 73% over the standard daily regimen, 
2MPZE2/2MP2 saving 69%, and 
.5MRZE/1.5MRZE2/2MR2 saving 67%.  
 
It should be emphasized that these moxifloxacin-
based regimens are under active study presently. 
No published trials yet support the safety and 
efficacy of these proposed regimens, but their 
promise is substantial. CDC is working in 
partnership with Bayer pharmaceuticals, the 
Global Alliance for TB Drug Development, the 
National Institutes of Health, and other 
collaborators to evaluate these potential 
improvements in treatment of TB. 
 
Table.  TB Treatment Regimen 
Implementation Costs -- See next page 
 
—Reported by Suzanne Marks, MPH, MA 
Div of TB Elimination 
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Notice of Updated Patient TB 
Educational Materials 
 
The Communications, Education, and Behavioral 
Studies Branch (CEBSB) is pleased to announce 
the availability of three patient TB educational 
materials that were updated in 2005:  
• Questions and Answers About TB 
• Tuberculosis: Get the Facts 
• Tuberculosis: The Connection Between TB 
and HIV  
  
Questions and Answers About TB uses a 
question-and-answer format to describe TB 
transmission, the differences between latent TB 
infection and active TB disease, treatment, and
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Table. TB Treatment Regimen Implementation Costs  
Total PHS Estimated DOT Estimated Estimated Estimated Percent
Regimen Doses Tot Med Cost Cost/Dose Personnel Cost Pt. Prod Loss Direct Costs Total Cost Cost Reduction
From Daily
Recommended 
Regimen Initial phase for active TB Standard
1 2HRZE (300, 600, 1500, 1200) 40 $235 $6 $1,118 $1,290 $1,354 $2,644
2 .5HRZE/1.5HRZE2 (300,600,1500,1200/900,600,3000,2800) 22 $198 $9 $615 $709 $813 $1,522
3 2HRZE3 (900, 600, 2500, 2000) 24 $221 $9 $671 $774 $892 $1,666
4 2HRE (300, 600, 1200) 40 $137 $3 $1,118 $1,290 $1,255 $2,545
Study 28 2MRZE (400, 600, 1500, 1200) 40 $399 $10 $1,118 $1,290 $1,517 $2,807
2MRZE2 (400, 600, 1500, 1200) 16 $159 $10 $447 $516 $607 $1,123
2MRZE3 (400, 600, 1500, 1200) 24 $239 $10 $671 $774 $910 $1,684
2MPZE2 (400, 900, 1500, 1200) 16 $341 $21 $447 $516 $788 $1,304
2MPZE2 (400, 1200, 1500, 1200) 16 $407 $25 $447 $516 $854 $1,370
.5MRZE/1.5MRZE2 (400,600,1500,1200/400,600,3000,2800) 22 $286 $13 $615 $709 $901 $1,610
.5MPZE/1.5MPZE2 (400,900,1500,1200/400,900,3000,2800) 22 $535 $24 $615 $709 $1,150 $1,860
.5MPZE/1.5MPZE2 (400,1200,1500,1200/400,1200,3000,2800) 22 $626 $28 $615 $709 $1,241 $1,950
2HPZE2 (600, 900, 1500, 1200) 16 $277 $17 $447 $516 $724 $1,240
2HRZE2 (900, 900, 1500, 1200) 16 $105 $7 $447 $516 $552 $1,068
Continuation phase for active TB
1a 4HR (300, 600) 90 $100 $1 $2,517 $2,902 $2,617 $5,518
1b,2a 4HR2 (900, 600) 36 $45 $1 $1,007 $1,161 $1,052 $2,213
3a 4HR3 (900, 600) 54 $68 $1 $1,510 $1,741 $1,578 $3,319
1c,2b 4HP1 (900, 600) 18 $153 $8 $503 $580 $656 $1,236
4HP1 (900, 900) 18 $227 $13 $503 $580 $730 $1,310
4HP2 (900, 600) 36 $305 $8 $1,007 $1,161 $1,312 $2,473
4HP2 (900, 900) 36 $454 $13 $1,007 $1,161 $1,460 $2,621
4a 7HR (300, 600) 155 $173 $1 $4,334 $4,998 $4,507 $9,504
4b 7HR2 (900, 600) 62 $78 $1 $1,734 $1,999 $1,812 $3,811
2MR (400, 600) 40 $208 $5 $1,118 $1,290 $1,326 $2,616
2MR2 (400, 600) 16 $83 $5 $447 $516 $531 $1,046
2MR3 (400, 600) 24 $125 $5 $671 $774 $796 $1,570
2MP2 (400, 900) 16 $265 $17 $447 $516 $712 $1,228
2MP2 (400, 1200) 16 $331 $21 $447 $516 $778 $1,294
Initial and continuation phases for active TB
1/1a 2HRZE/4HR 130 $336 $3 $3,635 $4,191 $3,970 $8,162
1/1b 2HRZE/4HR2 76 $281 $4 $2,125 $2,450 $2,406 $4,856 41%
1/1c 2HRZE/4HP1 58 $388 $7 $1,622 $1,870 $2,010 $3,880 52%
2/2a .5HRZE/1.5HRZE2/4HR2 58 $243 $4 $1,622 $1,870 $1,865 $3,735 54%
2/2b .5HRZE/1.5HRZE2/4HP1 (600 mg of P) 40 $350 $9 $1,118 $1,290 $1,469 $2,758 66%
3/3a 2HRZE3/4HR3 78 $289 $4 $2,181 $2,515 $2,470 $4,985 39%
4/4a 2HRE/7HR 195 $309 $2 $5,452 $6,287 $5,762 $12,049 -48%
4/4b 2HRE/7HR2 102 $215 $2 $2,852 $3,289 $3,067 $6,356 22%
2MRZE/2MR 80 $607 $8 $2,237 $2,579 $2,843 $5,423 34%
2MRZE2/2MR2 32 $243 $8 $895 $1,032 $1,137 $2,169 73%
2MRZE3/2MR3 48 $364 $8 $1,342 $1,548 $1,706 $3,254 60%
.5MRZE/1.5MRZE2/2MR2 38 $369 $10 $1,063 $1,225 $1,431 $2,657 67%
.5MPZE/1.5MPZE2/2MP2 (900 mg of P) 38 $800 $21 $1,063 $1,225 $1,862 $3,088 62%
.5MPZE/1.5MPZE2/2MP2 (1200 mg of P) 38 $957 $25 $1,063 $1,225 $2,019 $3,244 60%
2MPZE2/2MP2 (900 mg of P) 32 $606 $19 $895 $1,032 $1,500 $2,532 69%
2MPZE2/2MP2 (1200 mg of P) 32 $737 $23 $895 $1,032 $1,632 $2,664 67%
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how multidrug-resistant TB develops. This 
booklet, written at an 11th grade reading level, is 
appropriate for distribution to service providers, 
correctional facility staff, and patients. 
 
Tuberculosis: Get the Facts is a pamphlet on 
basic facts about TB transmission, infection, 
disease, and TB testing. Tuberculosis: The 
Connection Between TB and HIV (the AIDS 
virus) is a pamphlet on why it is important to 
know if a person has TB and HIV coinfection. 
Both of these pamphlets, written at a 5th grade 
reading level, are appropriate for distribution to 
patients or the general public. 
 
These and other TB materials may be viewed 
and downloaded in HTML and PDF versions from 
the DTBE website at www.cdc.gov/tb. They 
may also be ordered online by visiting 
www2.cdc.gov/nchstp_od/piweb/tborderform.asp. 
 
—Submitted by Scott McCoy, M.Ed. 
Div of TB Elimination 
 
Have You Visited the TB Education & 
Training Resources Website Lately? 




New features on the website: 
• Submit TB materials online. Share your 
organization's TB-related education and 
training materials by using the new online 
submission feature. 
 
• Subscribe to the TB Education and Training 
Resources E-newsletter. Find out how to 
subscribe to the monthly e-newsletter that 
features the “Highlight of the Month,” and 
“Additional Resources” in the database. Also 
view archives of previous e-newsletters. 
 
• Link to the TB Education and Training 
Network (TB ETN) webpage. Connect 
directly to this network of TB education and 
training professionals for opportunities to 
share resources and build education and 
training skills. 
 
—Submitted by Sandra Kong, MPH 




Workshop Helps Prepare Botswana 
for Scale-up of HIV Testing in TB 
Clinics 
 
Staff of two DTBE branches, the International 
Research and Programs Branch (IRPB) and the 
Communications, Education, and Behavioral 
Studies Branch (CEBSB), collaborated with 
CDC’s Global AIDS Program (GAP) to develop 
training materials and present a TB/HIV 
Surveillance Training of Trainers (TOT) 
Workshop last July in Gaborone, Botswana. 
Botswana’s Ministry of Health (MOH) and 
National TB Programme (BNTP), BOTUSA 
(CDC-GAP office in Botswana), the International 
Union Against TB and Lung Disease (IUATLD), 
and the World Health Organization (WHO) also 
supported the workshop. 
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The purpose of the workshop was to 
• Expand routine HIV testing (with counseling 
and referral) of TB patients in Botswana 
• Introduce the new TB recording forms that 
include variables on HIV status, antiretroviral 
therapy (ART) use, and isoniazid preventive 
therapy (IPT) use  
• Learn how to properly collect and record 
TB/HIV data using the TB treatment card and 
TB register  
• Build capacity by creating a cadre of district-
level trainers  
 
About 80 participants attended the workshop, 
including TB coordinators, community health 
nurses, and AIDS/STD unit representatives, from 
all 24 districts in Botswana. These participants 
will serve as trainers during Botswana’s 
upcoming national rollout of TB/HIV surveillance 
training to facility-level staff in each district. 
 
 
The facilitators used the “Teachback” 
methodology, allowing the participants to both 
receive and present core module materials that 
incorporate CDC and WHO best practices for 
TB/HIV surveillance. This methodology develops 
the training skills of participants, thereby building 
future training capacity in the country. 
 
The following TB/HIV core training modules were 
field tested at the workshop: 
 
• Introduction to TB/HIV 
• Expanding routine HIV testing of TB patients 
• TB recording and reporting and new HIV 
variables 
• Use of TB/HIV data at the facility level 
 
Updated versions of these core modules will be 
used in the Botswana districts and by other sub-
Saharan African countries that are experiencing 
high rates of TB/HIV coinfection. 
 
The remaining six modules, specifically targeting 
district-level staff, were also field tested at the 
workshop. These modules will not be used in the 
facility-level trainings, but did teach essential 
skills for TB/HIV recording and reporting at the 
district level, including 
 
• Supervision of surveillance activities 
• Using surveillance for monitoring and 
evaluation 
• Use of TB/HIV data at the district level 
• Using the Electronic TB Register 
• TB surveillance in HIV care and treatment 
settings 
• IPT surveillance 
• Development of training strategies (Action 
Plans) 
 
The workshop was well received by the course 
participants as well as the supporting facilitators. 
Dr. Robert Makombe of the WHO Regional Office 
for Africa (AFRO) and a facilitator for the training 
course, called the workshop “a most wonderful 
time spent learning and teaching new 
things, sharing experiences, and working out 
future areas of collaboration, all in a friendly and 
professional atmosphere.” 
 
Since the TOT workshop ended on August 1, 
2005, the DTBE/GAP team has worked with 
BNTP and BOTUSA staff to modify the core 
modules and prepare for a Botswana national 
rollout of TB/HIV facility-level trainings, 
scheduled to take place between October 2005 
and May 2006. To date, seven districts have 
conducted trainings for various health staff 
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involved in TB recording and reporting, including 
nurses, doctors, family welfare educators, 




The TB/HIV Surveillance Training-of-Trainers 
Workshop training materials are currently 
undergoing final revisions and will be submitted 
for CDC clearance in early 2006. These materials 
will be available for use in other GAP countries at 
that time. Please contact Lisa Nelson 
(lbn9@cd.gov), Kelly Stinson (kqw0@cdc.gov), 
or Bryan Kim (bkim@cdc.gov) for further 
information. 
 
—Submitted by Kelly Stinson, MPH 




New Association of Public Health 
Laboratories (APHL) 
TB Steering Committee Formed 
 
Following the publication of the 2004 APHL TB 
Task Force report, “The Future of TB Laboratory 
Services, A Framework for Integration, 
Collaboration, and Leadership,” the association 
will begin implementing the report 
recommendations. Heading this endeavor is a 
new APHL TB Steering Committee. The 
committee is a joint venture with APHL members, 
CDC staff, a National TB Controllers Association 
(NTCA) representative, and laboratorians from 
the clinical sector. It will also be tasked with 
reviewing other important TB laboratory and 
cross-cutting programmatic issues. 
 
There are three benchmarks that the Steering 
Committee will be tasked with implementing. 
Benchmark one suggests that an ongoing 
assessment of available TB laboratory services is 
needed to determine the current status and 
capacity of services and to identify unmet needs, 
obstacles to obtaining laboratory services, and 
opportunities for improvement. Benchmark two 
addresses the need for an assessment of the 
true costs of providing TB laboratory services. 
The third and final benchmark involves the 
development of a strategic plan for implementing 
and maintaining a systems approach for TB 
control. The Committee met at APHL 
headquarters on November 21 and 22, 2005, to 
strategize a plan of action for implementing these 
benchmarks. 
 
—Submitted by APHL TB Steering Committee:  
Nancy Warren, Chair, PA; John Bernardo, NTCA; 
Edward Desmond, CA; Wendy Gross, VA Medical 
Ctr, CT; Bruce Hanna, NY Univ School of Medicine; 
Nancy Hooper, MD; Ken Jost, TX; Anthony Tran, 
APHL; David Warshauer, WI; Michael Iademarco, 
John Ridderhof, and Tom Shinnick, CDC 
 
Laboratory Issues from the 
Northeastern TB Controllers Meeting 
Summary 
 
The Northeastern TB Controllers Meeting was 
held on September 26 and 27, 2005, at the New 
York State Department of Health, Albany, New 
York. The Northeast Regional Training and 
Medical Consultation Center in New Jersey 
serves the following states and cities: Maine, 
New Hampshire, Vermont, Rhode Island, 
Massachusetts, Connecticut, New Jersey, New 
York, Delaware, Maryland, Pennsylvania, West 
Virginia, Ohio, Indiana, Michigan, New York City, 
Philadelphia, Baltimore, Detroit, and Washington, 
DC. For the first time, TB laboratory partners 
from each of these jurisdictions were invited to 
attend the meeting. 
 
NUMBER 1, 2006 
 
19
Day one of the meeting included separate 
morning breakout sessions for the TB controllers 
and laboratorians, allowing them to discuss 
issues of significance in their particular realm. 
During the laboratory session, there were several 
key issues noted by the laboratory participants: 
 
• A discussion regarding funding brought to 
light the fact that laboratories do not feel that 
they are seen as equal partners in TB 
prevention and control. Federal guidelines 
(i.e., Healthy People 2010) are now requiring 
faster turnaround times by laboratories in 
identifying and reporting TB. However, to 
meet these shorter turnaround times, the 
laboratories must use more sophisticated 
and expensive diagnostic tools such as the 
Mycobacterium Tuberculosis Direct (MTD) 
assays and QuantiFERON-TB Gold (QFT-G). 
In addition, the costs of liquid media, probes, 
and reagents increase each year, as do 
workforce salaries and benefits. TB funding 
has remained level since 1995, and this lack 
of increased funding results in the decreased 
ability to keep pace with laboratory 
requirements. Flat funding affords less 
buying power for the laboratories. 
 
• Each year the TB Laboratory Upgrade 
component of the Cooperative Agreement 
requests laboratories to fill in a “true needs” 
budget assessment, but no additional funds 
for meeting these needs had been provided 
until FY 2005. However, the laboratories that 
received less funding in FY 2005 as a result 
of the funding formula did receive a slight 
increase to help make up for this shortfall. 
 
Several laboratory panel members also felt 
disconnected with CDC in terms of support and 
guidance during the Cooperative Agreement 
writing process. Still others felt that the goals 
CDC set are unrealistic without the promise of 
more financial support.  These funding issues 
must be dealt with at the federal and state level 
in order for change to occur. The APHL TB 
Steering Committee has been addressing TB 
funding issues and will continue to be committed 
to helping the TB laboratory find equality of 
funding. 
 
• A proposal was made that TB training and 
education for the performance of laboratory 
assays could be supported by the TB 
Regional Training and Medical Consultation 
Centers (RTMCCs), since they receive a 
large share of the total TB funding. 
 
The afternoon session consisted of a joint 
roundtable session with both program and 
laboratory members. The roundtable discussion 
focused on the QFT-G assay, including issues 
surrounding funding, transportation of 
specimens, and cost, which is estimated to be 
$35 per test. While laboratorians agree that the 
QTF-G data look encouraging, the 
aforementioned questions still need to be 
answered before implementation can take place. 
New York State is currently the only jurisdiction in 
the region performing the QFT-G assay; 
however, this is only done on Department of 
Corrections patients. This specialized population 
was chosen in order to address the specimen 
stability problem. Inmates are transported from 
the prison to a site closer to the laboratory where 
blood is drawn and samples can be processed 
immediately. 
 
Day two of the meeting was packed with plenary 
sessions on TB contact investigation guidelines, 
program evaluation plans, the role of the National 
TB Controllers Association (NTCA), 
implementation of QFT and real-time genotyping, 
surveillance in low-incidence populations, and 
the investigation of an M. bovis cluster in New 
York City. 
 
The overall sentiment from participants was 
positive towards the first joint meeting of TB 
controllers and laboratorians in the Northeast 
region. Attendees felt that the meeting provided a 
good forum for sharing information from their 
respective jurisdictions and learning from others. 
NUMBER 1, 2006 
 
20 
In general, TB controllers and their laboratory 
partners have worked hard to establish good 
working relationships. Joint meetings afford all 
parties involved the opportunity to work together 
to improve funding, understand the limitations of 
new procedures, and address the obstacles 
encountered in new testing methods. This 
speaks to the need for collaborative education for 
both groups, in order to improve communication 
and maximize the use of resources. Hopefully 
future meetings with more time for discussion will 
help alleviate some of these issues. 
 
For questions about APHL or the APHL TB 
Steering Committee, please contact Anthony 
Tran, HIV, STD, and TB program manager, at 
anthony.tran@aphl.org or at (240) 485-2783. 
 
—Submitted by Anthony Tran, MPH, MT(ASCP) 
Association of Public Health Laboratories 




Update on Surveillance Data: Release 
of 2004 Annual Report and Slide Set 
 
Beginning in 1953, through the cooperation of 
state and local health departments, CDC has 
been collecting information on the numbers of 
newly reported cases of TB disease in the United 
States. Since its initial publication in 1963 (then 
entitled Reported Tuberculosis Data, and now 
Reported Tuberculosis in the United States), the 
annual summary of TB surveillance has been 
revised periodically to improve the interpretation 
and dissemination of TB surveillance data. 
Reported Tuberculosis in the United States, 2004 
features the following methodological changes: 
 
• In contrast to previous annual summaries in 
which TB case counts of preceding years 
were not updated, the current summary 
reports the number of cases of confirmed TB 
for each year from 1993 to 2003 based on 
updated information. Therefore, case counts 
for these years may differ from those 
reported in the annual summaries previously 
published. 
• Tables 1–5, 20, 28, and 46, in addition to 
case count (numerator) updates, apply 
population updates (denominator) to 
calculate TB case rates for 1993–2004. 
• The method for calculating the annual 
percentage change in the TB case rate was 
modified. In contrast to methods used in 
previous summaries, “unrounded” figures are 
now applied to calculate the percentage 
change in the case rate, lending a degree of 
precision and accuracy greater than those 
reported in the past. 
 
Other notable changes and enhancements are 
as follows: 
 
• The slide set for Reported Tuberculosis in 
the United States, 2004, can be directly 
downloaded into PowerPoint format at 
http://www.cdc.gov/nchstp/tb/pubs/slidesets/
surv/surv2004/default.htm. 
• Slide sets for 1997–2003 can also be directly 
downloaded into PowerPoint format at 
http://www.cdc.gov/nchstp/tb/pubs/slidesets/
surv/default.htm. 
• Addition of a technical note to clarify a point 
of confusion generated by a note from the 
2003 report, in which two new species were 
added to the M. tuberculosis complex. 
 
Statistical highlights of Reported Tuberculosis in 
the United States, 2004, include the following: 
   
• 14,517 TB cases were reported to CDC from 
the 50 states and the District of Columbia, 
representing a 2.3% decrease from 2003  
• Foreign-born persons constituted 54% of the 
total number of cases in the United States in 
2004   
• The TB case rate declined to 4.9 per 100,000 
• 19 states reported increases in case counts  
• For the first time, Hispanics exceeded blacks 
as the racial/ethnic group with the largest 
percentage of all cases: 29% vs. 28%  
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• U.S.-born blacks represented 45% of TB 
cases in U.S.-born persons and more than 
one fifth of all cases   
• The TB case rate was 2.6 per 100,000 for 
U.S.-born persons and 22.8 for foreign-born 
persons    
• Asians continue to have the highest case 
rate among all racial and ethnic groups   
• The proportion of all cases with primary 
multidrug-resistant TB remained 
approximately 1.0%, and the proportion of 
these cases occurring in foreign-born 
persons increased to 73%  
  
Reported Tuberculosis in the United States, 
2004, released October 2005, is available in hard 
copy and is posted on the Internet at 
http://www.cdc.gov/nchstp/tb/surv/surv.htm). 
 
Following are suggested citations for hard copy 
and online versions: 
 
Hard copy: CDC. Reported Tuberculosis in the United 
States, 2004. Atlanta, GA: U.S. Department of Health 
and Human Services, CDC, September 2005.  
 
Online: Centers for Disease Control and Prevention. 
Reported Tuberculosis in the United States, 2004 
[online]. Atlanta, GA: U.S. Department of Health and 
Human Services, CDC; 2005. Available at 
http://www.cdc.gov/nchstp/tb/surv/surv2004/default.htm. 
 
—Reported by Valerie Robison, DDS, MPH, PhD 
Div of TB Elimination 
 
Updating the TB Biotechnology 
Engagement Project in the Republics 
of Armenia and Georgia, 2005 
 
Background. The Biotechnology Engagement 
Program (BTEP) is a congressionally mandated 
program residing in the U.S. Department of 
Health and Human Services (DHHS), Office of 
Global Health Affairs.1 The BTEP enables former 
biologic weapons scientists from Russia and 
Northern Eurasia to work collaboratively with 
U.S. experts in conducting operational research 
that addresses critical in-county public health 
concerns using evidence-based science. BTEP 
projects are funded for 12–36 months. Priority 
diseases funded through BTEP include TB, 
HIV/AIDS, hepatitis, influenza, other infectious 
diseases, and food and waterborne diseases. 
 
CDC staff, in collaboration with the Ministries of 
Health in the Republics of Armenia and Georgia, 
developed a TB BTEP project described in TB 
Notes No.1, 2003, called the “Development of 
Multiple-drug Resistant Tuberculosis Surveillance 
and National TB Program Evaluations, Republics 
of Armenia and Georgia.” This project, which was 
awarded 3 years of funding effective October 
2004, consists of the nine tasks further described 
in TB Notes No. 2, 2005. Tasks 1 (description of 
TB surveillance system in Armenia) and 2 
(evaluation of current TB surveillance system in 
Armenia) have been completed. Task 3 is to 
assess the prevalence of M. tuberculosis in the 
Republic of Armenia because of uncertainty 
around current estimates. 
 
TB in Armenia. Armenia has a 3.2 million 
population2 and is located between Turkey, 
Georgia, Iran, and Azerbaijan. It is divided into 11 
administrative regions (or marzes), with over a 
third (36%) of the country’s population residing in 
the capital of Yerevan. The collapse of the former 
Soviet Union in 1991 and subsequent social, 
political, and economic transitions have had a 
negative impact on health and healthcare in the 
newly independent states (Armenia, Azerbaijan, 
Belarus, Georgia, Kazakhstan, Kyrgyzstan, 
Republic of Moldova, Russian Federation, 
Tajikistan, Turkmenistan, Ukraine, and 
Uzbekistan). Population migration, decreases in 
life conditions, lack of essential health care 
services, and lack of access to essential drugs3 
have created conditions favorable for the rise and 
spread of infectious diseases, including TB. 
 
Before the collapse of the Soviet Union, TB 
surveillance and treatment systems in Armenia 
and each of the former Republics of the FSU 
followed the Soviet model and were centrally 
planned. After the collapse of the Soviet Union, 
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there was officially still a TB system in place in 
Armenia. However, in-country experts state that 
for several years after 1991, there was in reality 
no functioning TB system in the country. There 
was a subsequent two-fold increase in TB 
morbidity. The incidence (number of new cases 
per year) of TB in Armenia more than doubled 
from 932 in 1990 to 2146 in 2003.4 The number 
of TB cases notified or reported (WHO definition 
of a TB case notification which includes new and 
relapse cases) tripled during 1990–2003 from 
590 to 1538. 
 
With the assistance of foreign partners such as 
the International Committee of the Red Cross 
(ICRC), GTZ (the German equivalent of the US 
Agency for International Development), and 
WHO, the TB program in Armenia has started to 
rebuild. In December 2003, the Armenian 
National TB Program (NTP) was approved by the 
Armenian government. TB continues to be a 
major public health problem in Armenia; 
however, there have been no recent TB 
prevalence surveys done, nor is there accurate 
information about the magnitude of multidrug-
resistant TB (MDR TB). In the absence of 
knowledge about the magnitude of TB, it is 
imperative to conduct a TB prevalence survey to 
estimate the prevalence of TB in the country. 
 
According to WHO, conducting population-based 
surveys as epidemiological measurements for TB 
control can provide an accurate measure of 
bacteriologically confirmed disease. National TB 
prevalence surveys have been conducted in 
developing countries and used to measure 
decreases in TB prevalence due to successful 
implementation of short-course chemotherapy 
following WHO guidelines,5 set targets for NTP 
and gain political will and financial support for TB 
control,6-7 and show TB trends over time.8 
 
Task 3. The purpose of Task 3 is to conduct a 
cross-sectional population-based survey using 
multi-stage stratified cluster sampling in Yerevan, 
the capital of Armenia. This survey will provide 
much-needed insight on how to combine public 
health surveillance and public health action to not 
only support, but also enhance, Armenia’s NTP 
and further the country’s TB reform goals. 
 
—Reported by Nita Patel, MPH, Kashef Ijaz, MD, 
MPH, and Scott J.N. McNabb, PhD, MS 
Div of TB Elimination 
 
Nita Patel and Kashef Ijaz with the Armenian TB BTEP 
Team Members, Yerevan, Armenia, June 2005. 
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Conference on the Economics of TB 
Prevention and Control 
 
The second annual conference on the economics 
of TB prevention and control was held at the 
University of North Texas Health Science Center 
at Fort Worth on October 11 and 12, 2005 (c.f., 
photo below of attendees). The conference built 
on the previous gathering in Fort Worth in 2004. 
The purpose of the conference was to bring 
together national, state, and local TB officials and 
academics to explore techniques and tools for 
monitoring and evaluating TB programs, leading 
to enhanced efficiency and effectiveness. 
 
Organized by Dr. Peter Hilsenrath of the School 
of Public Health at the University of North Texas 
Health Science Center, this conference was 
supported by Task Order #10 of the TB 
Epidemiologic Studies Consortium. Task Order 
#10 began in 2003 at two locations: Hillsborough 
County (Tampa), Florida, and Tarrant County 
(Fort Worth), Texas. A primary objective of Task 
Order #10 is to develop techniques and tools to 
monitor and evaluate TB programs. 
 
Epidemiologists in Florida and Texas have 
compiled cost data and performance measures 
of national TB goals to help evaluate the 
efficiency and effectiveness of TB programs. 
Preliminary work has resulted in a number of 
presentations and publications, including two 
papers in the Annals of Epidemiology. The latest, 
authored by Thaddeus Miller, Steve Weis, and 
others, is titled “Using Cost and Health Impacts 
to Prioritize the Targeted Testing of Tuberculosis 
in the United States.” The paper compared TB 
programs for homeless and jail populations. It 
found that resources generate relatively better 
results among the homeless than among jail 
inmates. This suggests that for a given level of 
TB funds, efficiency would be improved by 
shifting resources to the homeless. The Florida 
and Texas teams presented some of these and 
other findings at a recent conference of the 
American and Canadian Evaluation Associations 
in Toronto on October 29, 2005. 
 
The Fort Worth conference emphasized both 
practical and theoretical issues on the first day. 
Following an update on Task Order #10, there 
was a presentation of the Florida experience and 
tool by Betial Teweldemedhin. Participants then 
heard a talk about the principles of cost 
accounting by Joseph Coyne of Washington 
State University, two presentations by Victoria 
Phillips, an economist with Emory University, 
about cost-effectiveness analysis, and a 
presentation by Travis Porco of the State of 
California Department of Health on epidemiology 
and the measurement of health outcomes. The 
second day focused more on implementation 
issues and the differing perspectives of local, 
state, and federal organizations. The day began 
with a presentation by Gerry Burgess Drewyer 
with the Tarrant County TB program about the 
primary concerns of local health departments 
such as hers. This was followed by two talks by 
state officials familiar with the allocation of 
resources to TB surveillance, control, and 
treatment. First, Keith Hughes discussed the 
evolution of budgeting for TB in Florida and what 
really matters most in determining these 
allocations. Second, Charles Wallace with the 
State of Texas provided valuable insights about 
how resources have been allocated in Texas for 
TB. This was followed by a presentation from 
Heather Duncan of CDC who offered a view from 
the federal perspective. 
 
In the afternoon of October 12, there was a 
return to theoretical issues with an overview of 
discounting by Todd Jewell of the University of 
North Texas at Denton. This helped participants 
understand the sometimes-arcane logic of 
economists and finance departments who do not 
typically view the value of money as static and 
commonly discount future revenues and costs for 
the purposes of decision making. The conference 
NUMBER 1, 2006 
 
24 
wrapped up with a roundtable discussion about 
accomplishments and directions for future work. 
 
The concept of compiling basic accounting data 
to measure costs and linking these with health 
outcome data is not a breakthrough in 
management thinking. However, there is growing 
realization throughout the United States and 
within international and federal circles (especially 
at CDC) that greater attention must be paid to 
efficiency and to monitoring and measuring 
health impacts. This extends well beyond simply 
producing at low cost. It also means being better 
at making difficult decisions about where to 
allocate scarce resources. 
 
One just has to look at the World Health 
Organization (WHO) as it transforms itself by 
results-based budgeting and management. Now 
in its fourth budgeting cycle based on program 
performance and health impacts, the Director 
General of the WHO, Dr. Jong-wook Lee, 
believes that the transition to results-based 
budgeting and management has been a 
“considerable success” in building a WHO-wide 
focus on results, improving the targeting of 
resources, and achieving greater accountability 
(WHO Budget 2006–2007). 
 
So, why not CDC and the state and local TB 
programs? 
 
As stated by CDC Director Julie Gerberding, MD, 
MPH, in a letter to partners, “We are refocusing 
our efforts to address goals that truly have an 
impact on people’s health and safety across their 
lifespan…Our new structure better aligns CDC to 
achieve these goals. Our new coordinating 
centers will help CDC's scientists collaborate and 
innovate across organizational boundaries, 
improve efficiency so that more money can be 
redirected to science and programs in our 
divisions, and improve the internal services that 
support and develop CDC staff.” 
 
As we work in an era of accelerating change, 
CDC can flourish by enhancing results-based 
decision-making. Results-based management is 
all about aligning TB goals and CDC agencywide 
health goals to the program planning process—
i.e., to program performance and the budget. 
Once done, it makes sense to fund programs 
(and projects within those programs) that support 
agreed-upon health goals and perform well, so 
as to achieve the results that ultimately lead to 
positive health impacts. 
 
The participants in Task Order #10 believe that 
our work has the potential to contribute to more 
efficient TB control and hope that future work will 
develop user-friendly products that can be tested 
in a variety of demonstration sites around the 
country. 
 
—Submitted by Peter Hilsenrath, Ph.D., Professor, 
Dept of Health Management and Policy, 
School of Public Health, 
University of North Texas Health Science Center, 
and Scott J.N. McNabb, Ph.D., M.S., 
Distinguished Consultant 
Div of TB Elimination 
 
  
Participants of the Economics of TB Prevention 
and Control Conference, Ft. Worth, TX, October, 
2005. 
 
Preliminary Findings of the 
NTCA/CDC Genotyping Survey 
 
At the request of attendees of last year's National 
TB Controllers Association (NTCA) meeting, a 
small NTCA/CDC workgroup formed to increase 
our understanding of the current needs of the 
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national genotyping program. The workgroup’s 
focus has been to determine what resources are 
available or required to assist states in managing 
genotyping data. An initial study conducted in 
2004 determined that many state and local TB 
control programs were at the planning and 
development stages for implementation of 
universal genotyping programs. 
 
A second NTCA/CDC web-based study in August 
2005 reassessed states’ use of genotyping data. 
Specifically, the study was designed to obtain 
feedback on improving the current universal 
genotyping program: how programs were using 
genotyping data, what programs would like to do 
differently, better, or more easily with genotyping 
surveillance, and how NTCA and CDC might be 
able to facilitate these improvements.   
 
A total of 49 (94%) of 52 TB programs completed 
the survey. Forty-six (94%) reported that they 
were conducting universal genotyping (submitting 
one isolate per culture-positive case). Of the 
three that do not conduct universal genotyping 
now, two plan to transition to universal 
genotyping by the end of 2006. Twenty-six (53%) 
programs mandated submission of isolates to a 
county or state public health laboratory. 
 
Isolate tracking. Forty-four (88%) programs 
reported having some system for tracking 
isolates, but only 15 (31%) had the capability of 
tracking isolates during the genotyping 
submission process that could provide an alert 
when results were delayed. 
 
Genotyping Data Management. Thirty-one (63%) 
of the programs received genotyping results 
directly at the TB program, while 14 (29%) 
received results via the state public health 
laboratory only. A majority of the programs 
reviewed genotyping results as soon as they 
were reported; 34 (69%) and 38 (78%) reviewed 
genotyping results to decide whether to request 
RFLP or conduct a cluster investigation, 
respectively. Three programs review data only 
two to three times per year, suggesting they were 
not using genotyping data to direct the 
implementation of real-time interventions. To 
manage the reports received from the reference 
laboratories, 24 (49%) programs merged new 
genotype reports with prior reports in a single 
cumulative Microsoft Excel spreadsheet, while 18 
(37%) used another database program such as 
Microsoft Access. 
 
Linking Data to Epidemiologic Information. 
Twelve (25%) programs routinely linked 
epidemiologic information to genotyping results 
on all of their isolates; 15 (31%) linked 
epidemiologic information only on clustered 
isolates. Under certain circumstances, such as 
assessing suspected outbreaks or unusual 
clusters, eight (16%) programs linked 
epidemiological information. Of the programs that 
linked epidemiologic and genotyping data to 
characterize clusters, more than half were able to 
do so by geographic distribution (72%), drug 
susceptibility (62%), country of origin (64%), race 
or ethnicity (56%), and other TB risk factors such 
as alcoholism or homelessness (74%). Only 10 
programs (20%) made no attempt to link 
genotype data with epidemiologic data. The 
following reasons emerged as potential barriers 
to making such linkages: lack of resources, few 
reported cases, and difficulty in determining 
which unique identifiers to use to link the data.    
 
Communication. Six (12%) of the programs 
routinely held cluster conferences to discuss the 
status of ongoing genotype cluster investigations, 
18 (37%) held meetings as needed, and 23 
(47%) held no conferences or meetings. 
Eighteen (37%) programs reported occasionally 
communicating with other programs. However, 
30 (61%) rarely or never communicated with 
neighboring jurisdictions or states to compare or 
discuss genotyping results. 
 
Satisfaction. Only four (8%) of the programs were 
very satisfied with their state’s current use of 
genotyping data. Many responders felt that their 
current program depended too much on one or 
two key personnel to review data (31%), they 
NUMBER 1, 2006 
 
26 
could not easily link epidemiologic information 
(31%), they needed more education on how to 
interpret results (33%), or they could not easily 
compare state results to national results (53%).      
 
This survey provided much-needed insight into 
the programmatic use of genotyping across the 
United States. Several important issues have 
emerged as challenges for continued success of 
the national genotyping program. Improving local 
access to useful data management tools that 
help facilitate linking epidemiologic variables and 
sharing interstate genotyping information is 
needed. Even though 61% of the programs 
reported rarely or never communicating with 
neighboring jurisdictions, about 80% of 
responders were willing to share genotyping 
results with other TB controllers, and another 
seven were willing to do so if certain criteria were 
met, such as approval from leadership and 
assurance of confidentiality. DTBE continues to 
collaborate with the NTCA Genotyping 
Workgroup to develop new tools to manage and 
query genotyping data. Specifically, we are 
currently developing an online system to help 
local TB programs share genotyping information 
related to interstate clusters. CDC is committed 
to improving the programmatic use of genotyping 
data for local interventions and will provide 
consultation and education to local programs. If 
programs have questions about genotyping 
laboratory procedures, they should call Lauren 
Cowen at (404) 639-1481 (los4@cdc.gov); for 
questions concerning the interpretation of 
genotyping results, call Patrick Moonan at (404) 
639-5310 (bng3@cdc.gov).     
 
—Submitted by Patrick Moonan, Epidemiologist  
Michele Hlavsa,  EIS Officer  
Div of TB Elimination  
and Phil Griffin, co-Chair 
NTCA Genotyping Workgroup 
Kansas Department of Health and Environment 
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Gaby Benenson, MPH, has accepted an offer to join 
the Division of Global Migration and Quarantine 
(DGMQ) as Senior Health Education Specialist, 
effective February 21, 2006. Gaby received her 
bachelor of science degree in health science from 
James Madison University in Harrisonburg, Virginia, 
then a masters degree in public health in health 
behavior and health education from the University of 
Michigan. Gaby joined CDC as an Association of 
Schools of Public Health fellow assigned to DTBE in 
1999 and was quickly hired by DTBE permanently 
upon completion of the fellowship in 2001. Gaby was 
instrumental in the development of numerous TB 
education and training related activities, including the 
Mantoux Tuberculin Skin Testing Materials, the 
www.findTBresources.org database, and the annual 
TB Education and Training Network meeting. Gaby 
also served on the DTBE Outbreak Evaluation Unit, 
and was involved in outbreak-related education and 
training activities in Indiana, as well as with the 
Hmong in California and Thailand. In her new position 
in DGMQ, Gaby will be responsible for establishing 
and implementing a strategic vision for ongoing 
training of DGMQ field staff and their many partners 
in the airports, in private industry, and in communities. 
We are happy that Gaby has this opportunity, but we 
will miss her very much.  
 
Puneet Dewan, MD, joined the International Research 
and Programs Branch of DTBE on December 2, 
2005, and he has been seconded to the World Health 
Organization, Southeast Asia Regional Office in New 
Delhi, India. Before joining CDC in 2001, he was an 
internal medicine resident at the University of 
Washington, Seattle, and earned an MD degree from 
the University of California at Los Angeles (UCLA). 
Puneet previously served as an Epidemic Intelligence 
Service Officer with DTBE’s International Research 
and Programs Branch and was the project officer for 
a variety of TB epidemiologic research and program-
building efforts in the former Soviet Union and 
Southeast Asia. He also previously served as a WHO 
consultant evaluating TB program collaborations with 
the private medical sector in India. From 2003 to 2005 
Puneet served in the Field Services and Evaluation 
Branch, DTBE, where he was assigned to the San 
Francisco Department of Public Health. In San 
Francisco, Puneet was responsible for the city-wide 
switch from tuberculin skin testing for M. tuberculosis 
infection to the use of blood assays for M. 
tuberculosis. He also conducted outbreak 
investigations, operational research, and locally 
implemented studies for the TB Epidemiologic 
Studies Consortium. 
 
Derrick Felix was selected for the Public Health 
Advisor position in Honolulu, Hawaii, and began his 
new assignment on November 28, 2005. Derrick 
recently completed a 1-year assignment with the Fort 
Wayne–Allen County Department of Health TB 
Control Program in Fort Wayne, Indiana. During this 
time, he provided leadership, direction, and technical 
assistance to the local public health department in the 
midst of a TB outbreak in the local African-American 
community. Derrick assisted with the development of 
policies, procedures, and plans necessary to meet the 
changing needs of the program.  He also mentored 
newly hired staff, trained them in how to conduct TB 
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control activities, reviewed all cases and suspects to 
ensure appropriate case management, developed 
and implemented monthly case conference, and 
created a database that is being used to store and 
analyze data collected by the program. Derrick joined 
DTBE’s Field Services and Evaluation Branch in April 
2003 and began his first assignment with the Chicago 
Department of Public Health TB Program in Chicago, 
Illinois. He led and participated in monthly case 
conferences; conducted surveillance activities, case 
management, and contact and source case 
investigations, and provided DOT. Derrick also 
participated in large screenings within worksites and 
schools. He developed a database to track contacts 
identified during contact investigations and made 
modifications to another database to analyze Class 
B1/B2 immigrant screening data. Additionally, Derrick 
participated in temporary duty assignments in 
Portland, Maine, to assist in a TB outbreak among the 
homeless; Augusta, Maine, to implement a database 
allowing outbreak analysis and oversight at the state; 
Fort Wayne, Indiana, to assist in an outbreak among 
the African-American community; and Baton Rouge, 
Louisiana, to assist with TB control activities during 
the aftermath of Hurricane Katrina. Prior to joining 
CDC, Derrick worked for the Florida Department of 
Health TB Program in Palm Beach County June 2002 
to April 2003. As a Health Services Representative, 
he provided DOT and case management to TB 
patients in the field and clinic settings. Derrick, a 
graduate of the University of Florida, has a BS degree 
in Health Science Education. 
 
Odile Ferroussier, MPH, has left DTBE after serving 
for 4 years in the International Research and 
Programs Branch. She co-led the formal evaluation of 
the pilot of the Binational Card Project; designed, 
implemented, and is currently analyzing a study to 
assess the cost-effectiveness of four MDR TB 
treatment strategies based on the use of standardized 
and individualized drug regimens in Peru; evaluated 
the cost of private-public mix partnerships to improve 
TB case detection in Kannur district in India; and 
taught and mentored staff in numerous operational 
research projects in Russia and Latin America. 
Currently Odile is working for the International Union 
Against TB and Lung Disease in the TB/HIV 
Department. She is coordinating the work of the 
International Advisory Committee for the Union's 
Integrated HIV care initiative, the goal being to 
integrate TB and HIV care in pilot areas in Benin, the 
Democratic Republic of Congo (DRC), and 
Myanmar. She is also overseeing the development of 
the information system for this initiative. Odile 
is developing the protocol and instruments for a 
survey of patient costs, to be administered to 
coinfected patients in DRC and Benin. Finally, she is 
adapting a TB Program Management course 
(originally in English) for francophone countries and 
organizing the first session to be held in Cotonou, 
Benin, in late November 2006. 
 
Stacy Harper has joined DTBE in the Clinical and 
Health Systems Research Branch as a Senior Public 
Health Advisor (PHA) and will work particularly on 
facilitating cross-branch activities and procurements. 
Stacy has served as a PHA for CDC for nearly 15 
years, with field assignments including West Palm 
Beach, Florida, Washington, DC, and San Diego, 
California. In these previous assignments she served 
as a disease intervention specialist (DIS), Training 
and Education Coordinator, and Surveillance 
Coordinator before coming to CDC headquarters in 
Atlanta. In her assignment as a Public Health Advisor 
and Training Specialist, she provided training, 
developed surveillance and epidemiology courses, 
and provided technical assistance to the STD/HIV 
Prevention Training Centers. She has served on 
details to San Antonio to assist Katrina evacuees; to 
the newly formed Office of Workforce and Career 
Development (OWCD); to the West Nile Virus 
program (blood transfusion and organ transplant 
team); to the Smallpox Vaccine Program Plan, 
training states for implementation of Smallpox 
Vaccine; and to SARS assignments. Most recently 
she served as a Project Officer for the National 
Center for Injury Prevention and Control, Division of 
Injury Response (proposed). She is the current 
President of the Watsonian Society and serves as 
Chair of the Professional Development Committee for 
the Society. Stacy holds degrees in optometry and 
music, and attended graduate school at the University 
of Washington in epidemiology. 
 
Jimmy Keller has accepted the Senior Public Health 
Advisor position with the Florida Bureau of TB and 
Refugee Health.  For the 14 years that Jimmy has 
worked in public health, this assignment to Florida will 
be his sixth geographic location of assignment.  He 
started at the Dade County Public Health Unit, Miami, 
Florida, in May 1991 as a Public Health Associate II, 
in the STD program.  In September 1992, he was 
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transferred to New York City, New York, where he 
worked in the STD program at the Ft. Greene Health 
Center, Brooklyn, and the Jamaica Health Center, 
Queens, until January 1995.  At that time, he 
accepted a position as a Supervisory Public Health 
Advisor with the New York City TB Program and 
served at the Morrisania Chest Clinic, Bronx and 
Chelsea Chest Clinic in Lower Manhattan. In May 
1998, Jimmy accepted the position as the Public 
Health Advisor (Special Projects Coordinator) with the 
Detroit, Michigan, TB Program. This assignment 
broadened his scope of experience beyond the realm 
of service delivery into issues of program 
management and performance. In January 2001, he 
accepted a transfer to the Ohio TB Program which 
brought him the responsibility of coordinating 
programmatic activities for a state-level TB program, 
including such things as contracting for TB medical 
consultant services and participating in planning for 
cooperative agreement fund allocations; development 
of funds carry-over requests; and personnel and 
staffing administration. In November 2003, Jimmy 
accepted the Public Health Advisor position at the 
North Carolina TB Program. Here he encountered the 
full spectrum of program management activities 
related to planning operational activities; organizing 
staff meetings; controlling funds expenditures; 
carrying out staffing functions related to preparing 
position descriptions and developing new positions; 
and directing focus on national TB objectives. Jimmy 
began his service in the role of Senior Public Health 
Advisor for the Florida Bureau of TB and Refugee 
Health on November 28, 2005. 
 
Kayla Laserson, ScD, has left DTBE. She has 
accepted an exciting new position as the Director of 
CDC’s field station in Kisumu, Kenya, managing a 
staff of 600 people and directing an international 
health portfolio that includes research and program 
activities for malaria, TB, HIV, and other emerging 
infectious diseases. She and her family moved to 
Kenya during the last week of January, and she 
assumed her new role on February 1, 2006. Though 
we in DTBE are happy for Kayla to have this 
wonderful opportunity, we are sad to see her leave 
the division, to which she has contributed so much 
since arriving as a new Epidemic Intelligence Service 
(EIS) officer in the International Research and 
Programs Branch (previously International Activities 
unit) in July 1997. During her nearly 9 years with 
DTBE, Kayla has made very significant contributions 
to the global control of TB as well as to the efforts to 
eliminate TB in the United States. One of her major 
areas of focus has been the improvement of TB 
control in Latin America. Her work in that area in 
DTBE has been built upon her previous years of 
experience living and working in the region, 
conducting research on malaria. As another part of 
her DTBE work with Latin America, in particular 
Mexico, and also building on her efforts to improve TB 
screening, treatment, and care among immigrants in 
the United States, Kayla led efforts to design and 
implement the very successful binational TB card 
referral project, which was launched in 2003. Since its 
inception and launch, this project with Mexico—which 
required extensive negotiations and consensus 
building among two federal governments, multiple 
state governments from both countries, as well as a 
number of commissions and nongovernmental 
organizations—has generated much-needed 
information on the volume of TB patients who migrate 
across the U.S.-Mexico border while under active 
treatment, and has helped ensure that these patients 
actually complete treatment. In addition to the 
binational referral project, Kayla has conducted 
extensive epidemiologic studies on multidrug-
resistant (MDR) TB, TB/HIV, and TB among 
healthcare workers; has led or contributed to multiple 
outbreak investigations in the region; and has worked 
with the Pan American Health Organization (PAHO) 
as the CDC representative to facilitate a number of 
TB program capacity-building and policy development 
exercises in the region as well. In addition to her work 
with Latin America, she has provided extensive 
technical assistance and epidemiologic expertise for 
DTBE’s work in Southeast Asia, Africa, and Eastern 
Europe. For Southeast Asia, she has worked closely 
with staff of other DTBE branches, the DTBE field 
assignee for Southeast Asia, and staff of the Division 
of Global Migration and Quarantine to improve the 
immigrant and refugee screening process through the 
conduct of a number of studies and capacity-building 
exercises. Within Africa, she has worked extensively 
to develop TB program capacity for a number of 
countries for conducting operations research as a 
way to empower TB program staff to use program 
data and resources to identify problems and make 
key improvements in program performance. 
Additionally, she developed and refined strategies for 
assessing TB drug quality within the TB program 
context to help ensure the availability of quality drugs 
for treating patients, and carried out extensive training 
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for the methodology with TB staff from a number of 
countries. At the global policy level, Kayla led the 
effort to develop and refine new case registry and 
treatment outcome definitions for MDR TB patients, 
which are now widely used as the standards for 
registration and cohort analysis of MDR TB by a large 
number of TB programs throughout the world 
implementing DOTS-Plus projects for the treatment 
and management of MDR TB. Furthermore, she has 
made significant contributions to efforts of the World 
Health Organization (WHO) to develop new reporting 
and recording standards to accommodate the new 
2006–2015 Stop-TB Global Plan’s call for integrating 
MDR TB and TB/HIV within the DOTS strategy. Last 
but not least, Kayla’s enthusiasm, love of teaching, 
and great epidemiologic talent have been integral and 
critical to DTBE’s success in attracting the best and 
the brightest EIS officers for several years running. 
Though she will be sorely missed, we know that Kayla 
will continue to make incredible contributions to public 
health in Kenya and the Africa region, where her 
talents are greatly needed. We wish her and her 
family the very best in their new life in Kenya and take 
comfort in the fact that she will continue to have 
impact on global TB control in her new position. 
 
Gabe Palumbo, MBA, MPH, has left DTBE and 
accepted a position with the Division of Global 
Migration and Quarantine as the Detroit Quarantine 
Station Officer in Charge. He began his new position 
on December 12, 2005. Gabe joined the DTBE field 
staff in 1993 with an assignment to the New York City 
TB Program. In 1996, he was reassigned to the New 
York State TB Control Program with responsibilities 
for both Nassau and Suffolk counties. Gabe was 
subsequently reassigned to the Wisconsin TB 
Program in 1997, where he provided consultation and 
technical advice on statewide TB program 
development and assistance to local jurisdictions. In 
January 1999, he was selected for the senior PHA 
position in Hawaii, where he was responsible for TB 
program management activities. In 2001, Gabe 
reported to Lansing, Michigan, where he was 
responsible for providing technical advice and 
assistance to the Michigan TB Program, as well as 
working with local health departments in TB 
prevention and control efforts. Most recently, Gabe 
was the senior PHA for the California TB program. 
During his tenure in this position, Gabe served as the 
Chief, Resource Planning and Management Section, 
with primary responsibility for managing TB Branch 
fiscal resources and contractual awards. 
 
Laura Jean Podewils, MS, PhD, has joined the 
Clinical and Health Systems Research Branch of the 
DTBE as an Epidemiologist for the Tuberculosis 
Trials Consortium (TBTC).  The TBTC’s main purpose 
is to carry out targeted clinical studies to investigate 
TB research questions that will improve TB treatment 
and prevention strategies.  Laura holds a doctorate in 
epidemiology from Johns Hopkins Bloomberg School 
of Public Health, and completed 2 years at CDC as 
an Epidemic Intelligence Service (EIS) Officer in the 
Respiratory and Enteric Viruses Branch of the 
Division of Viral and Rickettsial Diseases in June 
2005.  She has previous clinical trials experience 
working as a data manager and research associate 
for a multicenter trial assessing walking as a means 
to attenuate fatigue in women with breast cancer, and 
as the principal investigator for a randomized trial 
evaluating the role of a home-based exercise 
program on maintaining physical function in persons 
with Alzheimer’s disease.  In her new assignment, 
Laura will be serving as a project officer and 
epidemiologist in support of multiple TBTC trials. 
Laura’s initial activities include the assessment of the 
antibiotic moxifloxicin as a potential new 
antituberculosis agent and the assessment of side 
effects associated with the intermittent use of 
rifamycins for treatment of latent TB infection. 
 
Susan Spaethe of the Information Technology and 
Statistics Branch left DTBE on Feb. 3, 2006, having 
accepted a career promotion with the National Center 
for Public Health Informatics, in the BioSense 
Program. Susan joined DTBE 6 years ago as a 
Computer Specialist and became Team Leader 
for the Software Application Development Team, 
supporting the DTBE data management activities. 
She was also the DTBE Technical Contact for the 
CITS contractors, assisting DTBE/OD in managing 
our CITS resources. She performed these and many 
more duties, such as serving as our Combined 
Federal Campaign coordinator for several years, 
outstandingly well. She always held a can-do attitude 
toward the bureaucratic barriers that sometimes delay 
our progress as we attempt to meet our goals and 
objectives. We will miss her humor and friendship and 
wish her well. 
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CALENDAR OF EVENTS 
 
March 2–4, 2006 
10th Annual Conference of the International Union 
Against Tuberculosis and Lung Disease (IUATLD) 
North American Region  
Chicago, Illinois 




March 9-10, 2006 
The TB Cohort Review Process 
New York City, New York 
Charles P. Felton National TB Center at Harlem 
Hospital 
Tel: (212) 939-8258; fax: (212) 939-8259 
 
April 19–21, 2006 





April 24–28, 2006 
55th Annual EIS Conference 
Atlanta, GA 
Epidemic Intelligence Service, CDC 
http://www.cdc.gov/eis/conference/conference.htm 
 
April 26–29, 2006 
The Denver TB Course 
Denver, CO 




May 10, 2006 
TB Case Management and Contact Investigation 
Workshop 
Anaheim, California 
Francis J. Curry National TB Center 
This is a workshop for nurses, communicable disease 
investigators, and medical social workers who work in 
TB programs. It covers the basics of TB case 
management, the new contact investigation 
guidelines, medical management of TB/LTBI cases, 
and patient adherence, and is approved for 6.5 
continuing education hours. Faculty: Dr. Karen Smith, 
Carol Pozsik, and Barbara Cole, among others. For a 
complete course description and application 




June 12–15, 2006  
2006 National TB Controllers Workshop: "Eliminating 
TB: Fighting the Enemy"  
Division of Tuberculosis Elimination, CDC 
Atlanta, GA 
Sheraton Buckhead 
 
